Build Your Comparison

Side-by-side financial analysis
ISRG logo
ISRG
LLY logo
LLY
KO logo
KO
JNJ logo
JNJ
PEP logo
PEP
Try popular comparisons:

Stock Comparison

ISRG vs LLY vs KO vs JNJ vs PEP

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$144.48B
5Y Perf.+114.2%
LLY
Eli Lilly and Company

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1.04T
5Y Perf.+568.9%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$341.71B
5Y Perf.+77.7%
JNJ
Johnson & Johnson

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$550.40B
5Y Perf.+62.4%
PEP
PepsiCo, Inc.

Beverages - Non-Alcoholic

Consumer DefensiveNASDAQ • US
Market Cap$194.09B
5Y Perf.+7.4%

ISRG vs LLY vs KO vs JNJ vs PEP — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ISRG logoISRG
LLY logoLLY
KO logoKO
JNJ logoJNJ
PEP logoPEP
IndustryMedical - Instruments & SuppliesDrug Manufacturers - GeneralBeverages - Non-AlcoholicDrug Manufacturers - GeneralBeverages - Non-Alcoholic
Market Cap$144.48B$1.04T$341.71B$550.40B$194.09B
Revenue (TTM)$10.58B$72.25B$49.28B$92.15B$93.92B
Net Income (TTM)$2.98B$25.27B$13.70B$25.12B$8.24B
Gross Margin66.3%83.5%61.7%68.1%54.1%
Operating Margin30.5%45.9%29.3%26.1%12.2%
Forward P/E38.9x30.0x24.3x19.7x16.4x
Total Debt$303M$42.50B$45.49B$36.63B$49.90B
Cash & Equiv.$3.37B$7.16B$10.27B$24.11B$9.16B

ISRG vs LLY vs KO vs JNJ vs PEPLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ISRG
LLY
KO
JNJ
PEP
StockJun 20Jun 26Return
Intuitive Surgical,… (ISRG)100214.2+114.2%
Eli Lilly and Compa… (LLY)100668.9+568.9%
The Coca-Cola Compa… (KO)100177.7+77.7%
Johnson & Johnson (JNJ)100162.4+62.4%
PepsiCo, Inc. (PEP)100107.4+7.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: ISRG vs LLY vs KO vs JNJ vs PEP

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LLY leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. PepsiCo, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. JNJ also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇LLY emerged as the overall leader. Track its performance:
ISRG
Intuitive Surgical, Inc.
The Growth Angle

ISRG lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
LLY
Eli Lilly and Company
The Growth Play

LLY carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 44.7%, EPS growth 96.0%, 3Y rev CAGR 31.7%
  • 14.5% 10Y total return vs ISRG's 464.9%
  • Lower volatility, beta 0.52, current ratio 1.58x
  • PEG 1.04 vs JNJ's 35.11
Best for: growth exposure and long-term compounding
KO
The Coca-Cola Company
The Income Pick

KO is the clearest fit if your priority is income & stability.

  • Dividend streak 56 yrs, beta -0.23, yield 2.6%
Best for: income & stability
JNJ
Johnson & Johnson
The Momentum Pick

JNJ ranks third and is worth considering specifically for momentum.

  • +55.0% vs ISRG's -20.2%
Best for: momentum
PEP
PepsiCo, Inc.
The Value Play

PEP is the #2 pick in this set and the best alternative if value and dividends is your priority.

  • Lower P/E (16.4x vs 19.7x), PEG 5.04 vs 35.11
  • 3.9% yield, 54-year raise streak, vs KO's 2.6%, (1 stock pays no dividend)
Best for: value and dividends
See the full category breakdown
CategoryWinnerWhy
GrowthLLY logoLLY44.7% revenue growth vs KO's 1.9%
ValuePEP logoPEPLower P/E (16.4x vs 19.7x), PEG 5.04 vs 35.11
Quality / MarginsLLY logoLLY35.0% margin vs PEP's 8.8%
Stability / SafetyLLY logoLLYBeta 0.52 vs ISRG's 0.91
DividendsPEP logoPEP3.9% yield, 54-year raise streak, vs KO's 2.6%, (1 stock pays no dividend)
Momentum (1Y)JNJ logoJNJ+55.0% vs ISRG's -20.2%
Efficiency (ROA)LLY logoLLY22.7% ROA vs PEP's 7.7%, ROIC 41.8% vs 14.9%

ISRG vs LLY vs KO vs JNJ vs PEP — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
LLYEli Lilly and Company
FY 2025
Product
93.5%$61.0B
Collaboration and Other Revenue
6.5%$4.2B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
JNJJohnson & Johnson
FY 2024
Innovative Medicine
64.1%$57.0B
MedTech
35.9%$31.9B
PEPPepsiCo, Inc.

Segment breakdown not available.

ISRG vs LLY vs KO vs JNJ vs PEP — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLLYLAGGINGJNJ

Income & Cash Flow (Last 12 Months)

LLY leads this category, winning 5 of 6 comparable metrics.

PEP is the larger business by revenue, generating $93.9B annually — 8.9x ISRG's $10.6B. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to PEP's 8.8%. On growth, LLY holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricISRG logoISRGIntuitive Surgica…LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…JNJ logoJNJJohnson & JohnsonPEP logoPEPPepsiCo, Inc.
RevenueTrailing 12 months$10.6B$72.2B$49.3B$92.1B$93.9B
EBITDAEarnings before interest/tax$3.8B$34.7B$15.5B$31.4B$14.3B
Net IncomeAfter-tax profit$3.0B$25.3B$13.7B$25.1B$8.2B
Free Cash FlowCash after capex$2.8B$13.6B$12.6B$19.1B$7.7B
Gross MarginGross profit ÷ Revenue+66.3%+83.5%+61.7%+68.1%+54.1%
Operating MarginEBIT ÷ Revenue+30.5%+45.9%+29.3%+26.1%+12.2%
Net MarginNet income ÷ Revenue+28.2%+35.0%+27.8%+27.3%+8.8%
FCF MarginFCF ÷ Revenue+26.8%+18.8%+25.5%+20.7%+8.2%
Rev. Growth (YoY)Latest quarter vs prior year+23.0%+55.5%+12.1%+6.8%+5.6%
EPS Growth (YoY)Latest quarter vs prior year+18.8%+169.9%+18.2%+91.0%+66.7%
LLY leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

PEP leads this category, winning 5 of 7 comparable metrics.

At 23.7x trailing earnings, PEP trades at a 54% valuation discount to ISRG's 51.7x P/E. Adjusting for growth (PEG ratio), LLY offers better value at 1.66x vs JNJ's 35.11x — a lower PEG means you pay less per unit of expected earnings growth.

MetricISRG logoISRGIntuitive Surgica…LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…JNJ logoJNJJohnson & JohnsonPEP logoPEPPepsiCo, Inc.
Market CapShares × price$144.5B$1.04T$341.7B$550.4B$194.1B
Enterprise ValueMkt cap + debt − cash$141.4B$1.07T$376.9B$562.9B$234.8B
Trailing P/EPrice ÷ TTM EPS51.69x47.85x26.12x39.45x23.67x
Forward P/EPrice ÷ next-FY EPS est.38.94x30.00x24.27x19.73x16.43x
PEG RatioP/E ÷ EPS growth rate2.37x1.66x2.34x35.11x7.25x
EV / EBITDAEnterprise value multiple39.04x34.32x25.45x19.09x16.42x
Price / SalesMarket cap ÷ Revenue14.35x15.92x7.13x6.20x2.07x
Price / BookPrice ÷ Book value/share8.22x37.16x9.99x7.76x9.48x
Price / FCFMarket cap ÷ FCF58.01x115.64x64.52x27.74x25.30x
PEP leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

LLY leads this category, winning 5 of 9 comparable metrics.

LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $17 for ISRG. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PEP's 2.43x. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs PEP's 5/9, reflecting strong financial health.

MetricISRG logoISRGIntuitive Surgica…LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…JNJ logoJNJJohnson & JohnsonPEP logoPEPPepsiCo, Inc.
ROE (TTM)Return on equity+16.9%+101.2%+41.1%+31.7%+40.1%
ROA (TTM)Return on assets+14.8%+22.7%+13.1%+13.0%+7.7%
ROICReturn on invested capital+15.0%+41.8%+15.8%+20.7%+14.9%
ROCEReturn on capital employed+16.5%+46.6%+17.3%+17.6%+16.1%
Piotroski ScoreFundamental quality 0–968755
Debt / EquityFinancial leverage0.02x1.60x1.33x0.51x2.43x
Net DebtTotal debt minus cash-$3.1B$35.3B$35.2B$12.5B$40.7B
Cash & Equiv.Liquid assets$3.4B$7.2B$10.3B$24.1B$9.2B
Total DebtShort + long-term debt$303M$42.5B$45.5B$36.6B$49.9B
Interest CoverageEBIT ÷ Interest expense35.68x10.70x48.23x10.34x
LLY leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LLY leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in LLY five years ago would be worth $51,381 today (with dividends reinvested), compared to $11,518 for PEP. Over the past 12 months, JNJ leads with a +55.0% total return vs ISRG's -20.2%. The 3-year compound annual growth rate (CAGR) favors LLY at 35.1% vs PEP's -5.1% — a key indicator of consistent wealth creation.

MetricISRG logoISRGIntuitive Surgica…LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…JNJ logoJNJJohnson & JohnsonPEP logoPEPPepsiCo, Inc.
YTD ReturnYear-to-date-27.6%+2.0%+16.4%+11.4%+1.9%
1-Year ReturnPast 12 months-20.2%+40.7%+17.7%+55.0%+14.5%
3-Year ReturnCumulative with dividends+24.1%+146.7%+39.3%+48.3%-14.5%
5-Year ReturnCumulative with dividends+38.9%+413.8%+65.3%+55.8%+15.2%
10-Year ReturnCumulative with dividends+464.9%+1449.6%+115.0%+132.2%+79.6%
CAGR (3Y)Annualised 3-year return+7.5%+35.1%+11.7%+14.0%-5.1%
LLY leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.23 beta — it tends to amplify market swings less than ISRG's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 94.5% from its 52-week high vs ISRG's 67.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricISRG logoISRGIntuitive Surgica…LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…JNJ logoJNJJohnson & JohnsonPEP logoPEPPepsiCo, Inc.
Beta (5Y)Sensitivity to S&P 5000.91x0.52x-0.23x-0.03x-0.09x
52-Week HighHighest price in past year$603.88$1182.73$84.04$251.71$171.48
52-Week LowLowest price in past year$396.68$623.78$65.35$149.04$127.60
% of 52W HighCurrent price vs 52-week peak+67.4%+92.8%+94.5%+90.7%+82.8%
RSI (14)Momentum oscillator 0–10037.457.249.253.538.4
Avg Volume (50D)Average daily shares traded2.2M2.6M13.6M6.7M6.5M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — KO and JNJ and PEP each lead in 1 of 2 comparable metrics.

Analyst consensus: ISRG as "Buy", LLY as "Buy", KO as "Buy", JNJ as "Buy", PEP as "Hold". Consensus price targets imply 47.0% upside for ISRG (target: $598) vs 8.5% for KO (target: $86). For income investors, PEP offers the higher dividend yield at 3.92% vs LLY's 0.55%.

MetricISRG logoISRGIntuitive Surgica…LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…JNJ logoJNJJohnson & JohnsonPEP logoPEPPepsiCo, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHold
Price TargetConsensus 12-month target$597.78$1271.24$86.13$251.55$167.89
# AnalystsCovering analysts5545484045
Dividend YieldAnnual dividend ÷ price+0.5%+2.6%+2.1%+3.9%
Dividend StreakConsecutive years of raises11565654
Dividend / ShareAnnual DPS$6.00$2.04$4.87$5.57
Buyback YieldShare repurchases ÷ mkt cap+1.6%+0.4%+0.2%+0.4%+0.5%
Evenly matched — KO and JNJ and PEP each lead in 1 of 2 comparable metrics.
Key Takeaway

LLY leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PEP leads in 1 (Valuation Metrics). 1 tied.

Best OverallEli Lilly and Company (LLY)Leads 3 of 6 categories
Loading custom metrics...

ISRG vs LLY vs KO vs JNJ vs PEP: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ISRG or LLY or KO or JNJ or PEP a better buy right now?

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). PepsiCo, Inc. (PEP) offers the better valuation at 23. 7x trailing P/E (16. 4x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ISRG or LLY or KO or JNJ or PEP?

On trailing P/E, PepsiCo, Inc.

(PEP) is the cheapest at 23. 7x versus Intuitive Surgical, Inc. at 51. 7x. On forward P/E, PepsiCo, Inc. is actually cheaper at 16. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 1. 04x versus Johnson & Johnson's 35. 11x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — ISRG or LLY or KO or JNJ or PEP?

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +413.

8%, compared to +15. 2% for PepsiCo, Inc. (PEP). Over 10 years, the gap is even starker: LLY returned +1450% versus PEP's +79. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ISRG or LLY or KO or JNJ or PEP?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Intuitive Surgical, Inc. 's 0. 91β — meaning ISRG is approximately -488% more volatile than KO relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 2% for PepsiCo, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ISRG or LLY or KO or JNJ or PEP?

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ISRG or LLY or KO or JNJ or PEP?

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 8. 8% for PepsiCo, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 12. 2% for PEP. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ISRG or LLY or KO or JNJ or PEP more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 1. 04x versus Johnson & Johnson's 35. 11x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, PepsiCo, Inc. (PEP) trades at 16. 4x forward P/E versus 38. 9x for Intuitive Surgical, Inc. — 22. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ISRG: 47. 0% to $597. 78.

08

Which pays a better dividend — ISRG or LLY or KO or JNJ or PEP?

In this comparison, PEP (3.

9% yield), KO (2. 6% yield), JNJ (2. 1% yield), LLY (0. 5% yield) pay a dividend. ISRG does not pay a meaningful dividend and should not be held primarily for income.

09

Is ISRG or LLY or KO or JNJ or PEP better for a retirement portfolio?

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 0. 5% yield, +1450% 10Y return). Both have compounded well over 10 years (LLY: +1450%, ISRG: +464. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ISRG and LLY and KO and JNJ and PEP?

These companies operate in different sectors (ISRG (Healthcare) and LLY (Healthcare) and KO (Consumer Defensive) and JNJ (Healthcare) and PEP (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ISRG is a mid-cap high-growth stock; LLY is a mega-cap high-growth stock; KO is a large-cap quality compounder stock; JNJ is a large-cap quality compounder stock; PEP is a mid-cap income-oriented stock. LLY, KO, JNJ, PEP pay a dividend while ISRG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.